Trademark Alertz ®
Search
Trademark
Owner
Trademark: ITM 2128272
Word
ITM
ID
2128272
Trademark Type
Word
Status
Protected: Registered/protected
Application Date
28 July 2020
Registration Date
28 July 2020
Renewal Date
28 July 2030
Owner(s)
ITM Isotope Technologies Munich SE
Service
KINGS PATENT & TRADE MARKS ATTORNEYS PTY LTD
Goods and Services:
Class 5
:
Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]
;
theranostics in the field of precision oncology
;
radiopharmaceutical products, namely lutetium-containing precursors
;
solutions for radioactive labelling
;
radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours
;
target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope
;
radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC
;
177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]
;
radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer
;
radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications
;
Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases
;
radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases.
Class 10
:
Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations
;
controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance
;
radionuclide generators for radiopharmaceutical purposes.
Class 42
:
Conducting clinical trials at all stages and in various indications, particularly in oncology
;
conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET].
Class 44
:
Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology.